Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC)

被引：3
|
作者：
Morizane, Chigusa
Ueno, Makoto
Sasaki, Takashi
Nagashima, Fumio
Mizuno, Nobumasa
Shimizu, Satoshi
Hayata, Nozomi
Ikezawa, Hiroki
Suzuki, Takuya
Nakajima, Ryo
Dutcus, Corina E.
Ikeda, Masafumi
机构：
[1] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[2] Kanagawa Canc Ctr Hosp, Div Hepatobiliary & Pancreat Oncol, Yokohama, Kanagawa, Japan
[3] Canc Inst Hosp JFCR, Tokyo, Japan
[4] Kyorin Univ, Dept Med Oncol, Tokyo, Japan
[5] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi, Japan
[6] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[7] Eisai & Co Ltd, Tokyo, Japan
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.310
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
310
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Yi, Seong Yoon
    Park, Young Suk
    Kim, Hyo Song
    Jun, Hyun Jung
    Kim, Kyoung Ha
    Chang, Myung Hee
    Park, Min Jae
    Uhm, Ji Eun
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1141 - 1145
  • [42] Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors
    Schweitzer, Nora
    Kirstein, Martha M.
    Kratzel, Anna-Maria
    Mederacke, Young-Seon
    Fischer, Mareike
    Manns, Michael P.
    Vogel, Arndt
    LIVER INTERNATIONAL, 2019, 39 (05) : 914 - 923
  • [43] SECOND-LINE CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE SERIES
    Brungs, Daniel
    Aghmesheh, Morteza
    Sjoquist, Katrin
    Goldstein, David
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 168 - 168
  • [44] Response to letter 'Outcome of second-line chemotherapy for biliary tract cancer'
    Walter, Thomas
    Horgan, Anne M.
    McNamara, Mairead
    McKeeve, Liz
    Min, Trisha
    Hedley, David
    Serra, Stefano
    Krzyzanowska, Monika K.
    Chen, Eric
    Mackay, Helen
    Feld, Ronald
    Moore, Malcolm
    Knox, Jennifer J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1512 - 1513
  • [45] SECOND-LINE CHEMOTHERAPY BY FOLFIRINOX WITH UNRESECTABLE PANCREATIC CANCER (PHASE I, II STUDY)
    Kobayashi, N.
    Shimamura, T.
    Tokuhisa, M.
    Goto, A.
    Endo, I.
    Ichikawa, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [46] Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Myung Hwan Rho
    Suee Lee
    Young Suk Park
    Joon Oh Park
    Eun Mi Nam
    Hyo Rak Lee
    Hyun Jung Jun
    Kyong-Choun Chi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 757 - 762
  • [47] Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study)
    Kobayashi, Noritoshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Endo, Itaru
    Ichikawa, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [48] Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Rho, Myung Hwan
    Lee, Suee
    Park, Young Suk
    Park, Joon Oh
    Nam, Eun Mi
    Lee, Hyo Rak
    Jun, Hyun Jung
    Chi, Kyong-Choun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 757 - 762
  • [49] Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
    Park, Chan Su
    Sung, Min Je
    Kim, So Jeong
    Jo, Jung Hyun
    Lee, Hee Seung
    Chung, Moon Jae
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    Park, Jeong Youp
    CANCERS, 2022, 14 (17)
  • [50] Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
    Zong Hong
    Zhong Qian
    Zhao Ruihua
    Jin Shuiling
    Zhou Chuang
    Zhang Xiaojian
    Shi Jianxiang
    Qiao Shishi
    Han Jinming
    Jiang Miao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345